Acromegaly
📧 Sign up to get email alerts when something new happens for Acromegaly.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-05-13Clinical Trial Update: Treatment Patterns and Treatment Outcomes for Acromegaly
This completed clinical trial update analyzes how acromegaly is treated in practice and the associated patient outcomes.
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
Clinical trial update on the genetics of endocrine tumors focusing on familial isolated pituitary adenoma (FIPA), with acromegaly and gigant…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: KETOgenic Diet Therapy in Patients With ACROmegaly [NA]
A clinical trial evaluating ketogenic diet therapy for acromegaly caused by pituitary adenoma, currently recruiting.
-
EMA withdrawal · 2025-03-21EMA Withdrawn: Mycapssa (octreotide acetate) — Amryt Pharmaceuticals DAC
The EMA has withdrawn the marketing authorization for Mycapssa (octreotide acetate) for acromegaly.
-
CLINICAL_TRIALS trial_result · 2025-03-17Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) [Phase 2]
This is a Phase 2 study (ACROBAT Evolve) assessing the safety and efficacy of Paltusotine for acromegaly; the trial completed and results we…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-02-27EMA Authorised: Somavert (pegvisomant) — Pfizer Europe MA EEIG
The EU has authorized Somavert (pegvisomant) for acromegaly.
-
CLINICAL_TRIALS trial_result · 2025-02-17Clinical Trial Update: An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) [Phase 2]
A Phase 2 trial (ACROBAT Edge) evaluating paltusotine for acromegaly has completed enrollment and posted results.
-
CLINICAL_TRIALS withdrawal · 2025-02-13Clinical Trial Update: Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs
This clinical trial update reports the withdrawal of a study evaluating oral glucose tolerance testing in patients treated with somatostatin…
-
CLINICAL_TRIALS trial_result · 2025-01-31Clinical Trial Update: Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China
A completed real-world study in China evaluating lanreotide Autogel for acromegaly.
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: PegvisOMant and the Immune SystEm (PROMISE)
The PROMISE trial, sponsored by the University of Roma La Sapienza, studied pegvisomant in acromegaly with an emphasis on immune-system effe…
-
CLINICAL_TRIALS trial_result · 2024-12-24Clinical Trial Update: A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
A completed clinical trial update from Ipsen studying participants’ experiences with gastroenteropancreatic neuroendocrine tumors (GEP-NETs)…
-
EMA approval · 2024-12-18EMA Authorised: Signifor (pasireotide) — Recordati Rare Diseases
The EMA authorised Signifor (pasireotide) for acromegaly and pituitary ACTH hypersecretion. Recordati Rare Diseases is the marketing authori…
-
FDA approval · 2024-10-25FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Gland Pharma Limited)
FDA approved a supplemental application for Octreotide acetate submitted by Gland Pharma Limited.
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly [Phase 2]
Phase 2 study evaluating the safety, tolerability, and efficacy of IONIS-GHR-LRx in patients with acromegaly has completed enrollment with r…
-
FDA approval · 2024-09-27FDA Approved: BYNFEZIA PEN — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved BYNFEZIA PEN (octreotide acetate) under an original NDA from Sun Pharmaceutical Industries. The product is an autoinjector pen …
-
CLINICAL_TRIALS trial_result · 2024-09-23Clinical Trial Update: Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands
A completed clinical trial evaluated acromegaly patients resistant to conventional doses of first-generation somatostatin ligands.
-
CLINICAL_TRIALS research · 2024-09-19Clinical Trial Update: The RApid Switch From 1st Generation Somatostatin Analogues to PaSireOtiDe In Acromegaly
This clinical trial update notes a rapid switch from first-generation somatostatin analogues to pasireotide in patients with acromegaly, wit…
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies [Phase 4]
Phase 4 expanded-access study update for pasireotide shows completed status with results posted, enabling access for eligible patients in No…
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess.
This clinical trial update notes recruitment for a study on bone strength determinants in acromegaly (growth hormone excess) conducted in vi…
-
CLINICAL_TRIALS trial_result · 2024-07-24Clinical Trial Update: Effects of Sandostatin LAR® in Acromegaly [Phase 4]
This update reports the completion and results of a Phase 4 trial evaluating Sandostatin LAR in patients with acromegaly.
-
FDA approval · 2024-07-11FDA Approved: MYCAPSSA — Supplemental Application (Chiesi USA, Inc.)
The FDA approved a supplemental application for MYCAPSSA (oral octreotide) submitted by Chiesi USA, Inc.
-
FDA approval · 2024-07-09FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for octreotide acetate (ANDA 203765) submitted by Heritage Pharmaceuticals d/b/a Avet Pharmaceut…
-
FDA approval · 2024-07-09FDA Approved: OCTREOTIDE ACETATE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA granted supplemental approval for Octreotide Acetate from Heritage Pharmaceuticals (d/b/a Avet Pharmaceuticals Inc.).
-
CLINICAL_TRIALS research · 2024-06-11Clinical Trial Update: Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The study aims to characterize neuroendocrine mechanisms of adiposity to identify potential pharmacological targets using integrated experim…
-
FDA approval · 2024-05-21FDA Approved: LANREOTIDE ACETATE — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for lanreotide acetate (lanreotide) to treat acromegaly and gastroenteropancreatic ne…